Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome
Information source: University of California, Davis
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Fragile X-Associated Tremor/Ataxia Syndrome; Fragile X Premutation Carriers
Intervention: Memantine (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: University of California, Davis Official(s) and/or principal investigator(s):
Randi J Hagerman, MD, Principal Investigator, Affiliation: University of California, Davis
Overall contact:
Jennifer B Cogswell, Phone: 916-703-0331, Email: jennifer.cogswell@ucdmc.ucdavis.edu
Summary
The purpose of this study is to determine if memantine is effective in treating symptoms of
Fragile X-associated Tremor Ataxia Syndrome.
Clinical Details
Official title: Characterization and Treatment of CNS Abnormalities in Premutation Carriers: A Double-Blind Placebo-Controlled Trial of Memantine
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Improvement in neurocognitive functioning
Secondary outcome: Improvement in Cognitive ERP Deficits
Eligibility
Minimum age: 30 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Fragile X premutation carrier (CGG repeat 55-200)with neurological symptoms
Exclusion Criteria:
- Previous reaction to memantine
Locations and Contacts
Jennifer B Cogswell, Phone: 916-703-0331, Email: jennifer.cogswell@ucdmc.ucdavis.edu
UC Davis MIND Institute, Sacramento, California 95817, United States; Recruiting
Jennifer B Cogswell, Phone: 916-703-0331, Email: jennifer.cogswell@ucdmc.ucdavis.edu
Louise Gane, Phone: 916-703-0238, Email: louise.gane@ucdmc.ucdavis.edu
Randi J Hagerman, MD, Principal Investigator
University of Colorado Health Sciences Center, Aurora, Colorado 80045, United States; Recruiting
Maureen Leehey, MD, Principal Investigator
Additional Information
Starting date: September 2007
Last updated: June 25, 2010
|
